CRBP earnings analysis
What we found in CRBP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Corbus Pharmaceuticals reported a net loss of $23.0 million for Q1 2026, with an EPS of $(1.23), indicating a wider loss compared to $(1.39) in Q1 2025. Operating expenses surged to $24.3 million, driven by increased clinical development costs, reflecting the company's ongoing push in drug development despite not generating any revenue.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Wider Net Loss Year-over-Year
- Net loss for Q1 2026 was $23.0 million, compared to $17.0 million in Q1 2025.
- Increased Operating Expenses
- Operating expenses rose to $24.3 million in Q1 2026 from $19.8 million in Q1 2025.
- Higher R&D Costs
- R&D expenses increased to $19.8 million in Q1 2026, up from $15.6 million in Q1 2025.
- Cash Reserves Available
- The company had approximately $138.6 million in cash, cash equivalents, and investments at the end of Q1 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Costs
- Operating costs rose significantly with total operating expenses reaching $24.3 million, potentially unsustainable without revenue.
- Ongoing Cash Burn
- Cash used in operating activities for Q1 2026 was $25.6 million, reflecting continued negative cash flows.
- Regulatory Approval Delays
- The success of product candidates, such as CRB-701 and CRB-913, remains uncertain and dependent on regulatory approvals.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.23
What they said about what is next.
The company did not provide specific revenue or EPS guidance.
The filing reads worse than the one before it.
What came before.
- 10-K · March 9, 2026
- Corbus is a clinical‑stage biotech with two lead programs: CRB‑701 (ADC for Nectin‑4 cancers) and CRB‑913 (peripherally‑restricted CB1 inverse agonist for obesity). Financially the company widened losses in 2025 (net…
- 10-K · March 11, 2025
- Corbus Pharmaceuticals (CRBP) is a clinical-stage oncology and obesity company progressing three programs: CRB-701 (ADC, Phase 1 China & Western), CRB-601 (Phase 1 dose escalation) and CRB-913 (IND-enabling, Phase 1…
- 10-Q · November 7, 2023
- Corbus reported no product revenues and continues to operate at a loss while advancing its oncology pipeline. Cash and liquid investments were ~$29.4M at September 30, 2023, but management states this will not be…
- 10-Q · August 8, 2023
- Corbus Pharmaceuticals reported no revenue for Q2 2023, continuing its trend of significant operating losses. The company posted a net loss of approximately $8,784,000 for the quarter, an improvement compared to a loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CRBP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever